<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Errol R Norwitz, MD, PhD, MBA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H14419317"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Preterm birth (delivery prior to 37+0 weeks or 259 days of gestation) complicates 9 to 12 percent of births worldwide and is the leading cause of newborn morbidity and mortality [<a href="#rid1">1</a>]. A common reason for preterm birth is the occurrence of spontaneous preterm labor. Because tocolysis of preterm labor has been largely unsuccessful in preventing preterm birth, attention has focused on preventive strategies, such as <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation. Progesterone supplementation may be effective in some high-risk patients (short cervix), but it is not a panacea because prophylaxis has limited efficacy and many spontaneous preterm births occur in patients without this high risk factor [<a href="#rid2">2-5</a>]. </p><p>This topic will discuss issues related to <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation to reduce the risk of spontaneous preterm birth. However, progesterone supplementation is only one component of risk reduction. Risk factors for preterm birth and other potential interventions for reducing risk are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/140781.html" rel="external">"Spontaneous preterm birth: Overview of interventions for risk reduction"</a>.)</p><p class="headingAnchor" id="H14419324"><span class="h1">RATIONALE FOR PROGESTERONE SUPPLEMENTATION</span><span class="headingEndMark"> — </span>The rationale for <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation is that endogenous progesterone contributes to pregnancy maintenance in several ways; therefore, exogenous progesterone supplementation may enhance these actions [<a href="#rid6">6</a>].</p><p><a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">Progesterone</a> effects on pregnancy include:</p><p class="bulletIndent1"><span class="glyph">●</span>Corpus luteum <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> production is critical for maintaining the pregnancy until the placenta takes over this function at seven to nine weeks of gestation. Removing the corpus luteum [<a href="#rid7">7</a>] or administering a progesterone receptor antagonist [<a href="#rid8">8</a>] readily induces abortion before seven weeks (49 days) of gestation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subsequently, placental <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> production maintains uterine quiescence [<a href="#rid9">9-11</a>]. Functional withdrawal of progesterone activity at the level of the uterus appears to occur proximate to the onset of labor both at term and preterm, without a significant change in serum progesterone levels in the weeks preceding labor [<a href="#rid9">9-16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progesterone-related immune modulation may act to counter pro-inflammatory pathways, both systemic and intrinsic to the uterus, thereby protecting against preterm labor and birth [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In vitro, <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> prevents apoptosis in fetal membrane explants under both basal and proinflammatory conditions [<a href="#rid18">18,19</a>] and thus may protect from preterm prelabor rupture of membranes and, in turn, preterm labor and birth.</p><p></p><p>However, circulating levels of endogenous <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> in the third trimester are already very high, are sufficient to saturate progesterone receptors, and do not increase with exogenous progesterone administration, so it is unclear why exogenous supplementation might have biologic effects. In addition, idiopathic and stress-associated preterm and term labor are associated with an increase in reproductive tract nuclear progesterone metabolizing enzymes; therefore, increasing local progesterone levels should have no or minimal effects. One theory to explain possible efficacy in some clinical scenarios is that exogenous vaginal progesterone may directly alter the vaginal microbiome or alter the inflammatory response to aberrant microbial states by its effects on local glucocorticoid receptors.</p><p class="headingAnchor" id="H14419338"><span class="h1">CANDIDATES FOR PROGESTERONE SUPPLEMENTATION</span><span class="headingEndMark"> — </span>The existing literature suggests that the efficacy of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation for preventing preterm birth depends primarily on appropriate patient selection, which remains controversial. The specific pathogenic pathway leading to spontaneous preterm birth is likely to be important as well [<a href="#rid20">20-22</a>]. Since spontaneous preterm birth is the final common pathway of several pathogenic processes, many of which involve reduction in the expression or activity of the progesterone receptor, a single intervention such as progesterone supplementation is unlikely to benefit all patients at risk or have the same degree of risk reduction in all patient populations. In vitro and animal research suggests that the type of progestin, formulation, dose, route of administration, and plasma concentration (which varies among patients receiving progestins) also impact efficacy [<a href="#rid23">23-25</a>].</p><p class="headingAnchor" id="H1060444226"><span class="h2">Singleton pregnancy with a short cervix</span><span class="headingEndMark"> — </span>In asymptomatic patients with a singleton pregnancy and midtrimester short cervical length (≤25 mm), vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation reduces the rate of spontaneous preterm birth and improves neonatal outcome. (See  <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Obstetric history'</a> and  <a class="medical medical_review" href="/z/d/html/450.html" rel="external">"Short cervix before 24 weeks: Screening and management in singleton pregnancies", section on 'Rationale for measuring cervical length'</a>.)</p><p>In a meta-analysis of individual participant data from five high-quality randomized trials including a total of 974 participants, compared with the placebo, daily vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> administration resulted in statistically significant reductions in [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Preterm birth &lt;33 weeks of gestation (14.1 versus 22.5 percent; relative risk [RR] 0.62; 95% CI 0.47-0.81)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preterm birth &lt;36 weeks (28 versus 35 percent; RR 0.80), &lt;35 weeks (21 versus 30 percent; RR 0.72), &lt;34 weeks (17 versus 26 percent; RR 0.65), &lt;32 weeks (12 versus 19 percent; RR 0.64), &lt;30 weeks (10 versus 14 percent; RR 0.70), and &lt;28 weeks (8 versus 11 percent; RR 0.67)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous preterm birth &lt;33 weeks (12 versus 17 percent; RR 0.70) and &lt;34 weeks (15 versus 20 percent; RR 0.72) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory distress syndrome (5 versus 10 percent; RR 0.47, 95% CI 0.27-0.81)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Composite neonatal morbidity and mortality (8 versus 14 percent; RR 0.59, 95% CI 0.38-0.91)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Birthweight &lt;1500 (10 versus 16 percent; RR 0.62) and &lt;2500 g (29 versus 36 percent; RR 0.82)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal intensive care unit admission (17 versus 25 percent; RR 0.68).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal deaths were also reduced, but the confidence interval crossed 1.0 (7 in 498 [1 percent] versus 15 in 476 [3 percent]; RR 0.44, 95% CI 0.18- 1.07).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maternal adverse events, congenital anomalies, and adverse neurodevelopmental and health outcomes at two years of age did not differ between groups. </p><p></p><p>The daily dose of vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> used in the trials varied from 90 to 200 mg. Treatment was initiated at 18 to 25 weeks of gestation and continued through 34 to 36 weeks. Subgroup analysis suggested these variables did not significantly affect the results.</p><p>The American College of Obstetricians and Gynecologists (ACOG) recommends vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> for asymptomatic patients with a singleton pregnancy with a short cervix without a previous history of preterm birth [<a href="#rid27">27</a>]. ACOG also considers it an option for asymptomatic patients with a singleton pregnancy with a short cervix and a previous history of preterm birth but also considers cerclage an option for these patients. We agree with this recommendation.</p><p class="headingAnchor" id="H1852602222"><span class="h2">Twin pregnany with a short cervix</span><span class="headingEndMark"> — </span>A meta-analysis of individual patient data from six randomized trials including 95 patients with twin gestations and midtrimester cervical length ≤25 mm found that vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> reduced preterm birth &lt;33 weeks and a composite of neonatal morbidity and mortality [<a href="#rid28">28</a>]. These data and recommendations for pregnancy monitoring and management are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/131147.html" rel="external">"Twin pregnancy: Management of pregnancy complications", section on 'Approach to patients with a short cervix'</a>.)</p><p class="headingAnchor" id="H14419373"><span class="h1">PREGNANCIES WHERE THE BENEFIT OF PROGESTERONE SUPPLEMENTATION IS UNPROVEN</span><span class="headingEndMark"> — </span>The benefit of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation in pregnant people at high risk of preterm birth, but without a short cervix, is not supported by strong evidence. Some of these clinical scenarios are reviewed below.</p><p class="headingAnchor" id="H3287295099"><span class="h2">Singleton pregnancy with prior preterm birth</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal </strong><strong>progesterone</strong> – In a 2022 meta-analysis limited to assessing the efficacy and safety of vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> to prevent recurrent preterm birth and adverse perinatal outcomes in singleton gestations with a history of spontaneous preterm birth (seven small and three large trials, 2958 patients), vaginal progesterone reduced the risk of preterm birth &lt;37 weeks (RR 0.64, 95% CI 0.50-0.81, very low-quality evidence) and &lt;34 weeks (RR 0.62, 95% CI 0.42-0.92, very low-quality evidence); however, the reductions were not statistically significant after restriction to trials at low risk of bias and adjustment for small-study effects [<a href="#rid29">29</a>]. Based on these findings and prospective observational data from a large study of inner-city pregnant patients in the US [<a href="#rid30">30</a>], ACOG recommends against use of vaginal progesterone to prevent recurrent preterm birth [<a href="#rid27">27</a>]. The author and section editor of this topic agree with this recommendation.</p><p></p><p class="bulletIndent1">The Society for Maternal-Fetal Medicine recommends a shared decision-making process regarding use of vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> for primary prevention of recurrent preterm birth without input of cervical length (including those with a cervical length ≥25 mm), especially if a progesterone formulation for preterm birth prevention was used in a previous pregnancy [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">The use of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> to prevent recurrent spontaneous preterm birth remains controversial and another UpToDate section editor does offer vaginal progesterone to these patients [<a href="#rid32">32</a>]. The 2022 meta-analysis discussed above did show a benefit from vaginal progesterone before restriction to trials at low risk of bias and adjustment for small-study effects [<a href="#rid29">29</a>]. Another meta-analysis of randomized trials in patients with singleton gestations and previous spontaneous preterm birth found that vaginal progesterone reduced preterm birth &lt;34 and &lt;37 weeks compared with 17-OHPC, although the difference at &lt;34 weeks was not statistically significant when sensitivity analysis was restricted to trials at low risk of bias (12.2 versus 13.9 percent; RR 0.87, 95% CI 0.57-1.32) [<a href="#rid33">33</a>]. In addition, secondary analysis of data from a randomized trial suggests that vaginal progesterone is associated with reduced cervical shortening and rates of cervical shortening in patients with singleton pregnancies and a previous singleton spontaneous preterm birth [<a href="#rid34">34</a>]. Lastly, translational data suggest that vaginal progesterone prevents cervical remodeling, uterine contractility, inflammation-induced pathology, and immune activation [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxyprogesterone caproate</strong><strong> (17-OHPC)</strong> – In 2003, Meis and coinvestigators randomly assigned 459 patients with a documented history of spontaneous singleton preterm birth &lt;37 completed weeks to weekly intramuscular injections of 17-OHPC or placebo beginning at 16 to 20 weeks of gestation and continuing until 36 weeks [<a href="#rid4">4</a>]. Active prophylaxis significantly reduced the risk of preterm birth at all gestational ages studied. </p><p></p><p class="bulletIndent1">However, in 2020, a randomized placebo-controlled multicenter international trial (PROLONG) that assessed the safety and efficacy of 17-OHPC in over 1700 patients with a singleton gestation and past history of preterm birth found that the intervention did not significantly reduce preterm birth &lt;35 weeks or fetal/early infant death [<a href="#rid35">35</a>]. </p><p></p><p class="bulletIndent1">In 2023, additional analysis of the data from these two trials, other randomized trials, and observational studies led the United States Food and Drug Administration (FDA) to conclude that use of Makena, the only commercially available 17-OHPC medication for prevention of recurrent preterm birth, is not supported by available evidence and withdrew its approval of the medication [<a href="#rid36">36</a>]. The American College of Obstetricians and Gynecologists (ACOG) concurred with this assessment [<a href="#rid27">27</a>].</p><p></p><p></p><p class="headingAnchor" id="H14419380"><span class="h2">Positive fetal fibronectin test</span><span class="headingEndMark"> — </span>Although a positive cervicovaginal fetal fibronectin (fFN) test is a risk factor for spontaneous preterm birth, minimal information on use of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation in such pregnancies is available. In the OPPTIMUM trial, patients with a positive fFN test and risk factors for preterm birth were included in the study population [<a href="#rid37">37</a>]. Vaginal progesterone supplementation did not improve obstetric, neonatal, or childhood outcomes in this trial.</p><p class="headingAnchor" id="H610172263"><span class="h2">Uterine anomaly or assisted reproductive technology</span><span class="headingEndMark"> — </span>Patients with some uterine anomalies and those who conceive with assisted reproductive technology appear to be at increased risk of preterm birth from a variety of mechanisms. The effectiveness of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> therapy for prevention of spontaneous preterm birth in these patients is unknown [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/6788.html" rel="external">"Assisted reproductive technology: Pregnancy and maternal outcomes"</a> and  <a class="medical medical_review" href="/z/d/html/5418.html" rel="external">"Congenital uterine anomalies: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2262641772"><span class="h2">Unselected twin pregnancies</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/131147.html" rel="external">"Twin pregnancy: Management of pregnancy complications", section on 'Overview'</a>.)</p><p class="headingAnchor" id="H14419387"><span class="h2">After preterm prelabor rupture of membranes</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/120959.html" rel="external">"Preterm prelabor rupture of membranes: Management and outcome", section on 'Supplemental progesterone'</a>.)</p><p class="headingAnchor" id="H14419401"><span class="h2">Threatened or established preterm labor</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Progesterone supplementation'</a>.)</p><p class="headingAnchor" id="H1144008455"><span class="h2">Maintenance therapy after threatened preterm labor</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/6795.html" rel="external">"Management of pregnancy after resolution of an episode of acute idiopathic preterm labor", section on 'Initiation of progesterone supplementation'</a>.)</p><p class="headingAnchor" id="H450693"><span class="h1">SAFETY, SIDE EFFECTS, AND ADVERSE EFFECTS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Composite risk data </strong>– In a 2021 meta-analysis of individual participant data from randomized trials evaluating progestins for preventing preterm birth (30 trials, &gt;11,600 participants), there was a nonsignificant increase in composite maternal complications (gestational hypertension, preeclampsia, gestational diabetes, maternal infection including chorioamnionitis) with <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation (vaginal progesterone: relative risk [RR] 1.14, 95% CI 0.93-1.40; <a class="drug drug_general" data-topicid="16452" href="/z/d/drug information/16452.html" rel="external">hydroxyprogesterone caproate</a> [17-OHPC]: RR 1.17, 0.97-1.42) compared with no supplementation, mostly as a result of increased gestational hypertension and maternal infection events; however, individual outcomes were uncertain [<a href="#rid39">39</a>]. The OPPTIMUM trial of vaginal progesterone prophylaxis for preterm birth, a large trial with the longest duration of follow-up (children at two years of age), found no increase in risk of any major complication in mothers or offspring up to two years of age [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of developing gestational diabetes</strong> – Both diabetogenic and antidiabetogenic effects have been attributed to <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a>; the net effect on risk of developing gestational diabetes in exposed pregnancies is unclear. In a 2019 meta-analysis (seven observational studies, four randomized trials) evaluating the risk of glucose intolerance in pregnant people who received a progestin for prevention of preterm birth, 17-OHPC was associated with an increased risk of developing gestational diabetes mellitus (11.9 versus 6.6 percent, risk ratio 1.73, 95% CI 1.32-2.28) while vaginal progesterone was not (6.5 versus 7.4 percent, risk ratio 0.82, 95% CI 0.50-1.12) [<a href="#rid40">40</a>]. A statistically significant difference was not reported in any of the randomized trials, but a meta-analysis of these trials alone was not performed. Moderate heterogeneity may have accounted for the statistical difference in glucose tolerance noted in the overall analysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of developing venous thrombosis</strong> – As there is no clinical evidence that vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> or 17-OHPC are associated with an increased risk of venous thrombosis, we use these drugs to reduce the risk of spontaneous preterm birth, when indicated, in patients with a history of venous thrombosis. The package inserts of all progesterone preparations and progestins in the United States carry a warning that a history of or current thrombophlebitis or venous thromboembolic disorders is a contraindication to use. The US Food and Drug Administration requires this warning because estrogen-progestin contraceptives are associated with an increased risk of venous thrombosis and they believe there is inadequate information to determine whether specific progesterone preparations or progestins used alone are also associated with an increased risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local side effects</strong> – Minor side effects are related to the route of administration and include injection site reactions for 17-OHPC and vaginal irritation or discharge for vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of teratogenesis</strong> – Initiation of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation begins at 16 weeks, which is well past the period of embryogenesis. No significant teratogenic effects have been reported. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term risk of developmental effects</strong> – A meta-analysis of two trials (890 children) found no increased risk of impaired neurodevelopment in children aged six months to eight years exposed to <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> during the second or third trimester of pregnancy [<a href="#rid41">41</a>]. Mental health, sexual or gender orientation, and pubertal development were not evaluated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of cancer in offspring</strong> – A retrospective population-based cohort study of &gt;18,000 mother-child dyads reported a possible small absolute increase in cancer among 234 offspring of mothers who received 17-OHPC during pregnancy between 1959 and 1966; 70 percent received treatment in the first trimester (41 percent for threatened abortion) [<a href="#rid42">42</a>]. At 60-years follow-up, 23 cancers had been diagnosed in 17-OHPC-exposed offspring. First-trimester exposure was associated with an increased risk of any cancer in offspring (incidence rate 29.6 versus 13.7 per 100,000 persons; adjusted hazard ratio 2.57, 95% CI 1.59-4.15). The highest risk was for colorectal, prostate, and pediatric brain cancers, with no increase in breast cancer risk. No comparison was made between risk of cancer in offspring and risk in the mother (or father), an approach that could have helped adjust for numerous confounding demographic, social, environmental, and genetic factors. Whether this association is germane to the current use of 17-OHPC to prevent preterm birth, in which treatment is initiated at 16 to 20 weeks, is not known.</p><p></p><p class="headingAnchor" id="H22816692"><span class="h1">PROGESTERONE PREPARATIONS</span></p><p class="headingAnchor" id="H3261164075"><span class="h2">Natural or micronized progesterone</span><span class="headingEndMark"> — </span>Natural <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> is typically administered vaginally. The advantage of vaginal progesterone is its high uterine bioavailability since uterine exposure occurs before the first pass through the liver. It has few systemic side effects, but vaginal irritation can be bothersome, and the drug needs to be administered daily. Doses of 90 to 400 mg have been effective, beginning as early as 18 weeks of gestation. We use 100 mg administered vaginally each evening; however, in some areas a 200 mg suppository may be more readily available and less costly. A vaginal suppository can be prepared by a compounding pharmacy utilizing commercially available standardized kits.</p><p>Other options include a 100 mg micronized <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> vaginal tablet or an 8 percent vaginal gel containing 90 mg micronized progesterone per dose. Both preparations are commercially available in the United States but not approved for prevention of preterm birth in cervical shortening. In 2012, the US Food and Drug Administration (FDA) concluded the data in the manufacturer's application did not sufficiently support the efficacy of progesterone 8 percent gel compared with placebo in reducing the risk of preterm births before 33 completed weeks of gestation among pregnant people with a short cervical length, but the drug was safe in this population [<a href="#rid43">43</a>]. The FDA was critical of the statistical methods used in the key trial and noted that most of the apparent treatment benefit occurred in non-United States centers. Since 2012, an additional trial and meta-analysis have supported the efficacy of vaginal progesterone in singleton pregnancies with a short cervical length and it is widely used off-label for this indication. (See <a class="local">'Singleton pregnancy with a short cervix'</a> above.)  </p><p class="headingAnchor" id="H1712923789"><span class="h2">Oral progesterone</span><span class="headingEndMark"> — </span>An oral micronized preparation of natural <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> also exists. In an individual patient data meta-analysis, preterm birth &lt;34 weeks was reduced by 40 percent (relative risk [RR] 0.60, 95% CI 0.41-0.90), but data were limited to two trials with a total of 181 patients [<a href="#rid39">39</a>]. A daily dose of 400 mg is common [<a href="#rid44">44,45</a>], although doses have varied widely. Reported side effects, which are less than with synthetic progesterone, include sleepiness and fatigue [<a href="#rid46">46,47</a>]. The author of this topic does not use oral progesterone for preterm birth prevention.</p><p class="headingAnchor" id="H31325196"><span class="h2">Hydroxyprogesterone caproate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16452" href="/z/d/drug information/16452.html" rel="external">Hydroxyprogesterone caproate</a> (17-OHPC) is a synthetic progestogen with minimal to no androgenic activity. </p><p>Makena (United States brand name) is a 17-OHPC preparation approved in 2011 by the FDA to reduce the risk of recurrent preterm birth in pregnant people with a singleton pregnancy who have a history of a prior spontaneous preterm delivery [<a href="#rid48">48</a>]. However, in October 2020 and October 2022, FDA advisors voted to withdraw Makena from the market based in part on findings of the international PROLONG trial in which administration of 17-OHPC to patients with a previous spontaneous preterm birth did not reduce the risk for recurrent PTB (spontaneous or indicated) [<a href="#rid35">35,49,50</a>]. In March 2023, the manufacturer announced plans to voluntarily withdraw it from the market in the coming months [<a href="#rid51">51</a>]. On April 5, 2023, the FDA withdrew its approval of Makena because a postmarketing confirmatory trial and studies did not show a clinical benefit [<a href="#rid36">36</a>]. The FDA found no clinically significant benefit when analyzed by race (Black versus non-Black), region (US versus non-US), by history of spontaneous preterm birth (one versus more than one previous spontaneous preterm birth), and by composite risk level (no risk factor versus at least one risk factor versus at least two risk factors). Clinicians should discuss these issues with patients who are currently taking Makena and offer them the choice of continuing treatment until 37 weeks or immediately discontinuing treatment. The FDA did not identify any harms from continuing or discontinuing treatment. However, medication supply may be limited.  </p><p>Physicians may request a licensed pharmacist to compound a 17-OHPC preparation tailored to an individual patient's particular medical needs, but should be aware of regulations and spectrum of quality concerns related to this practice and the FDA's determination that the drug is not effective for reducing recurrent spontaneous preterm birth [<a href="#rid36">36,52-56</a>]. ACOG does not endorse use of compounded 17-OHPC preparation for prevention of recurrent preterm birth [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H940799031"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114351.html" rel="external">"Society guideline links: Preterm labor and birth"</a>.)</p><p class="headingAnchor" id="H14419429"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Singleton gestation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Short cervical length</strong> –For pregnant people with a singleton pregnancy with a short cervix on ultrasound examination, we discuss vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation. Uncertainty regarding risk reduction and its magnitude exists, so not administering supplemental progesterone is also reasonable. Providers should discuss the option of prophylactic progesterone supplementation with patients, highlighting uncertainty regarding benefit but lack of serious short-term safety concerns. (See <a class="local">'Candidates for progesterone supplementation'</a> above and <a class="local">'Safety, side effects, and adverse effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior spontaneous preterm birth</strong> – The use of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> to prevent recurrent spontaneous preterm birth regardless of cervical length remains controversial. The author and section editor of this topic do not use it for this indication but another UpToDate section editor does offer it. ACOG recommends against use of vaginal progesterone to prevent recurrent preterm birth. The Society for Maternal-Fetal Medicine recommends a shared decision-making process. (See <a class="local">'Singleton pregnancy with prior preterm birth'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other scenarios</strong> – Routine <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation does not appear to be useful for preventing preterm birth in the setting of preterm prelabor rupture of membranes or after an episode of arrested preterm labor. There is no information on efficacy in patients with a positive fetal fibronectin test. The effect in patients with a cerclage is unclear. (See <a class="local">'After preterm prelabor rupture of membranes'</a> above and <a class="local">'Positive fetal fibronectin test'</a> above and <a class="local">'Threatened or established preterm labor'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple gestation </strong>–<strong> </strong>Treating twin pregnancies with a short cervix with vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> may be beneficial for prolonging gestation. Cerclage is another option. (See  <a class="medical medical_review" href="/z/d/html/131147.html" rel="external">"Twin pregnancy: Management of pregnancy complications", section on 'Approach to patients with a short cervix'</a>.).</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Walani SR. Global burden of preterm birth. Int J Gynaecol Obstet 2020; 150:31.</a></li><li><a class="nounderline abstract_t">Petrini JR, Callaghan WM, Klebanoff M, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005; 105:267.</a></li><li><a class="nounderline abstract_t">da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188:419.</a></li><li><a class="nounderline abstract_t">Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348:2379.</a></li><li><a class="nounderline abstract_t">Norman JE, Bennett P. Preterm birth prevention-Time to PROGRESS beyond progesterone. PLoS Med 2017; 14:e1002391.</a></li><li><a class="nounderline abstract_t">O'Brien JM, Lewis DF. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety. Am J Obstet Gynecol 2016; 214:45.</a></li><li><a class="nounderline abstract_t">Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet Gynecol Surv 1978; 33:69.</a></li><li><a class="nounderline abstract_t">Peyron R, Aubény E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993; 328:1509.</a></li><li><a class="nounderline abstract_t">Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med 1999; 341:660.</a></li><li><a class="nounderline abstract_t">Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000; 21:514.</a></li><li class="breakAll">Norwitz ER, Lye SJ. Biology of parturition. In: Creasy &amp; Resnick’s Maternal-Fetal Medicine, 6th ed, Creasy RK, Resnick R, Iams JD, et al (Eds), Elsevier, Philadelphia 2009. p.69.</li><li><a class="nounderline abstract_t">Condon JC, Jeyasuria P, Faust JM, et al. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proc Natl Acad Sci U S A 2003; 100:9518.</a></li><li><a class="nounderline abstract_t">Oh SY, Kim CJ, Park I, et al. Progesterone receptor isoform (A/B) ratio of human fetal membranes increases during term parturition. Am J Obstet Gynecol 2005; 193:1156.</a></li><li><a class="nounderline abstract_t">Renthal NE, Chen CC, Williams KC, et al. miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor. Proc Natl Acad Sci U S A 2010; 107:20828.</a></li><li><a class="nounderline abstract_t">Mesiano S, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reprod Sci 2011; 18:6.</a></li><li><a class="nounderline abstract_t">Lockwood CJ, Stocco C, Murk W, et al. Human labor is associated with reduced decidual cell expression of progesterone, but not glucocorticoid, receptors. J Clin Endocrinol Metab 2010; 95:2271.</a></li><li><a class="nounderline abstract_t">Shah NM, Lai PF, Imami N, Johnson MR. Progesterone-Related Immune Modulation of Pregnancy and Labor. Front Endocrinol (Lausanne) 2019; 10:198.</a></li><li><a class="nounderline abstract_t">Luo G, Abrahams VM, Tadesse S, et al. Progesterone inhibits basal and TNF-alpha-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth. Reprod Sci 2010; 17:532.</a></li><li><a class="nounderline abstract_t">Kumar D, Springel E, Moore RM, et al. Progesterone inhibits in vitro fetal membrane weakening. Am J Obstet Gynecol 2015; 213:520.e1.</a></li><li><a class="nounderline abstract_t">Manuck TA, Esplin MS, Biggio J, et al. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. Am J Obstet Gynecol 2016; 214:376.e1.</a></li><li><a class="nounderline abstract_t">Manuck TA, Stoddard GJ, Fry RC, et al. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system. Am J Obstet Gynecol 2016; 215:622.e1.</a></li><li><a class="nounderline abstract_t">Manuck TA, Lai Y, Meis PJ, et al. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2011; 205:135.e1.</a></li><li><a class="nounderline abstract_t">Kuon RJ, Shi SQ, Maul H, et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol 2010; 202:455.e1.</a></li><li><a class="nounderline abstract_t">O'Sullivan MD, Hehir MP, O'Brien YM, Morrison JJ. 17 alpha-hydroxyprogesterone caproate vehicle, castor oil, enhances the contractile effect of oxytocin in human myometrium in pregnancy. Am J Obstet Gynecol 2010; 202:453.e1.</a></li><li><a class="nounderline abstract_t">Caritis SN, Venkataramanan R, Thom E, et al. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. Am J Obstet Gynecol 2014; 210:128.e1.</a></li><li><a class="nounderline abstract_t">Romero R, Conde-Agudelo A, Da Fonseca E, et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol 2018; 218:161.</a></li><li class="breakAll">ACOG Practice Advisory. Updated Clinical Guidance for the Use ofProgesterone Supplementation for the Prevention ofRecurrent Preterm Birth. April 2023 https://www.acog.org/en/clinical/clinical-guidance/practice-advisory/articles/2023/04/updated-guidance-use-of-progesterone-supplementation-for-prevention-of-recurrent-preterm-birth?utm_source=higher-logic&amp;utm_medium=email&amp;utm_content=apr-07&amp;utm_campaign=acog2023-rounds (Accessed on April 10, 2023).</li><li><a class="nounderline abstract_t">Romero R, Conde-Agudelo A, Rehal A, et al. Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data meta-analysis. Ultrasound Obstet Gynecol 2022; 59:263.</a></li><li><a class="nounderline abstract_t">Conde-Agudelo A, Romero R. Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis. Am J Obstet Gynecol 2022; 227:440.</a></li><li><a class="nounderline abstract_t">Nelson DB, Lafferty A, Venkatraman C, et al. Association of Vaginal Progesterone Treatment With Prevention of Recurrent Preterm Birth. JAMA Netw Open 2022; 5:e2237600.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM). Electronic address: <span class="__cf_email__" data-cfemail="3c4c495e4f7c4f515a5112534e5b">[email protected]</span>, SMFM Publications Committee. Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate. Am J Obstet Gynecol 2023; 229:B2.</a></li><li><a class="nounderline abstract_t">Berghella V, Gulersen M, Roman A, Boelig RC. Vaginal progesterone for the prevention of recurrent spontaneous preterm birth. Am J Obstet Gynecol MFM 2023; 5:101116.</a></li><li><a class="nounderline abstract_t">Boelig RC, Locci M, Saccone G, et al. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2022; 4:100658.</a></li><li><a class="nounderline abstract_t">O'Brien JM, Defranco EA, Adair CD, et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2009; 34:653.</a></li><li><a class="nounderline abstract_t">Blackwell SC, Gyamfi-Bannerman C, Biggio JR Jr, et al. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial. Am J Perinatol 2020; 37:127.</a></li><li class="breakAll">Makena (hydroxyprogesterone caproate injection) Information. U.S. Food and Drug Administration (FDA). Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/makena-hydroxyprogesterone-caproate-injection-information (Accessed on April 06, 2023).</li><li><a class="nounderline abstract_t">Norman JE, Marlow N, Messow CM, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet 2016; 387:2106.</a></li><li class="breakAll">Likis FE, Andrews JC, Woodworth AL, et al. Progestogens for Prevention of Preterm Birth. Comparative Effectiveness Review No. 74. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I), AHRQ Publication No. 12-EHC105-EF; Agency for Healthcare Research and Quality, Rockville, MD 2012.</li><li><a class="nounderline abstract_t">EPPPIC Group. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet 2021; 397:1183.</a></li><li><a class="nounderline abstract_t">Pergialiotis V, Bellos I, Hatziagelaki E, et al. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis. Am J Obstet Gynecol 2019; 221:429.</a></li><li><a class="nounderline abstract_t">Simons NE, Leeuw M, Van't Hooft J, et al. The long-term effect of prenatal progesterone treatment on child development, behaviour and health: a systematic review. BJOG 2021; 128:964.</a></li><li><a class="nounderline abstract_t">Murphy CC, Cirillo PM, Krigbaum NY, et al. In utero exposure to 17a-hydroxyprogesterone caproate and risk of cancer in offspring. Am J Obstet Gynecol 2022; 226:132.e1.</a></li><li class="breakAll">Background Document for Meeting of Advisory Committee for Reproductive Health Drugs. January 20, 2012. NDA 22-139. Progesterone gel (8%) http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM287987.pdf.</li><li><a class="nounderline abstract_t">Ashoush S, El-Kady O, Al-Hawwary G, Othman A. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. Acta Obstet Gynecol Scand 2017; 96:1460.</a></li><li><a class="nounderline abstract_t">Glover MM, McKenna DS, Downing CM, et al. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol 2011; 28:377.</a></li><li><a class="nounderline abstract_t">O'Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30:687.</a></li><li><a class="nounderline abstract_t">Thornton JG. Progesterone and preterm labor--still no definite answers. N Engl J Med 2007; 357:499.</a></li><li class="breakAll">US Food and Drug Administration. Statement on Makena [press release]. United States Department of Health and Human Services 2011. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm249025 (Accessed on May 09, 2011).</li><li class="breakAll">https://www.regulations.gov/docket?D=FDA-2020-N-2029&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on October 06, 2020).</li><li class="breakAll">Perrone M. FDA pushes to remove pregnancy drug, company pushes back. AP News. Available at: https://apnews.com/article/science-health-business-medication-premature-births-d257b0871a2a41668a97a6a83a0a7340 (Accessed on October 21, 2022).</li><li class="breakAll">Covis Pharma Responds to Presiding Officer’s Report Summarizing FDA Advisory Committee Hearing. Covis Pharma. Available at: https://covispharma.com/index.php/covis-pharma-responds-to-presiding-officers-report-summarizing-fda-advisory-committee-hearing/ (Accessed on March 30, 2023).</li><li><a class="nounderline abstract_t">Chang J, Zhao Y, Zhao W, et al. Quality assessment of compounded 17-hydroxyprogesterone caproate. Am J Obstet Gynecol 2014; 210:47.e1.</a></li><li class="breakAll">https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm402614.htm (Accessed on March 16, 2017).</li><li class="breakAll">https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm308546.htm (Accessed on March 16, 2017).</li><li class="breakAll">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310215.htm (Accessed on March 16, 2017).</li><li><a class="nounderline abstract_t">Fried I, Beam AL, Kohane IS, Palmer NP. Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth. JAMA Intern Med 2017; 177:1689.</a></li></ol></div><div id="topicVersionRevision">Topic 16560 Version 143.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32524596" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global burden of preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684150" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592250" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12802023" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28949963" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Preterm birth prevention-Time to PROGRESS beyond progesterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26558340" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/341008" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8479487" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10460818" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The control of labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041447" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endocrine and paracrine regulation of birth at term and preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041447" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endocrine and paracrine regulation of birth at term and preterm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12886011" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157129" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Progesterone receptor isoform (A/B) ratio of human fetal membranes increases during term parturition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079000" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20889955" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237167" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Human labor is associated with reduced decidual cell expression of progesterone, but not glucocorticoid, receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30984115" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Progesterone-Related Immune Modulation of Pregnancy and Labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20360593" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Progesterone inhibits basal and TNF-alpha-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070709" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Progesterone inhibits in vitro fetal membrane weakening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26692181" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418444" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21600550" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20452487" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20452486" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 17 alpha-hydroxyprogesterone caproate vehicle, castor oil, enhances the contractile effect of oxytocin in human myometrium in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24113254" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29157866" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29157866" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34941003" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35460628" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Does vaginal progesterone prevent recurrent preterm birth in women with a singleton gestation and a history of spontaneous preterm birth? Evidence from a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36315147" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Association of Vaginal Progesterone Treatment With Prevention of Recurrent Preterm Birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37061078" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37543143" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vaginal progesterone for the prevention of recurrent spontaneous preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35562009" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19918965" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31652479" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31652479" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26921136" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26921136" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33773630" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31132340" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33112462" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The long-term effect of prenatal progesterone treatment on child development, behaviour and health: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : In utero exposure to 17a-hydroxyprogesterone caproate and risk of cancer in offspring</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : In utero exposure to 17a-hydroxyprogesterone caproate and risk of cancer in offspring</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28949010" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21380990" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A randomized trial of micronized progesterone for the prevention of recurrent preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17899572" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671259" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Progesterone and preterm labor--still no definite answers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671259" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Progesterone and preterm labor--still no definite answers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671259" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Progesterone and preterm labor--still no definite answers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671259" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Progesterone and preterm labor--still no definite answers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671259" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Progesterone and preterm labor--still no definite answers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24200163" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Quality assessment of compounded 17-hydroxyprogesterone caproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24200163" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Quality assessment of compounded 17-hydroxyprogesterone caproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24200163" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Quality assessment of compounded 17-hydroxyprogesterone caproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24200163" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Quality assessment of compounded 17-hydroxyprogesterone caproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973537" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
